This is a randomized study evaluating the effect of routinely collecting a standardized questionnaire of heart failure health status during heart failure clinic visits. Participants will be randomized to early or delayed implementation of a validated health-related quality of life survey (the Kansas City Cardiomyopathy Questionnaire). Participants randomized to early implementation will be given this 12-question survey at each heart failure clinic visit at the beginning of the study; their heart failure clinician will have access to survey results but will continue to manage participants based on standard treatment practice. Patients randomized to delayed implementation will start receiving the survey at each clinic visit one year later. By comparing the health status and treatment rates between early and delayed implementation, this study will determine the impact of standardized health status assessment on patient outcomes and clinician decision-making.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
1,249
Health status assessment will be completed using the well-validated Kansas City Cardiomyopathy Questionnaire-12 prior to or at the time of heart failure clinic visits.
Stanford Hospital & Clinics
Stanford, California, United States
Kansas City Cardiomyopathy Questionnaire-12 Score
The first KCCQ-12 score collected one year after randomization will be compared between the KCCQ-12 and usual care arms. KCCQ-12 scores will be collected in the usual care arm starting one year after randomization. Scores will be adjusted for baseline KCCQ-12 in both arms. This will be the primary effectiveness outcome. KCCQ-12 has 4 domains (Physical Limitation Score, Symptom Frequency Score, Quality of Life Score, Social Limitation Score) and one Summary Score. Domain scores are scaled 0-100, and the overall score is the average of the domain scores. For the domain and overall scores, 0 denotes the lowest reportable health status and 100 the highest. Higher values represent a better outcome.
Time frame: Collected at the first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization
Kansas City Cardiomyopathy Questionnaire-12 Response Rate
Frequency of KCCQ-12 response at each clinic visit among patients in the KCCQ-12 arm. This will be the primary implementation outcome. The rate will be calculated as the number of responses divided by the total number of requests to complete the survey.
Time frame: 1 year
Percentage of Patients on Beta-blocker Therapy Among Patients With Reduced Ejection Fraction
Beta-blocker therapy use among the sub-group of patients with left ventricular ejection fraction ≤ 40%.
Time frame: Evaluated at the first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization
Median Dose of Beta-Blocker Therapy Among Patients With Reduced Ejection Fraction
Among those patients on beta-blocker therapy, the specific medication and dose will be collected.
Time frame: Evaluated at the first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization
Percentage of Patients on Renin-Angiotensin-Aldosterone System Inhibitors Among Patients With Reduced Ejection Fraction
Use of any renin-angiotensin-aldosterone system inhibitors among the sub-group of patients with left ventricular ejection fraction ≤ 40%. These include angiotensin-converting enzyme inhibitor, angiotensin receptor blockers, or angiotensin receptor-neprilysin inhibitors.
Time frame: Collected at the first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization
Median Dose of Renin-Angiotensin-Aldosterone System Inhibitors Among Patients With Reduced Ejection Fraction
Among those patients on renin-angiotensin-aldosterone system inhibitors with left ventricular ejection fraction ≤ 40%, the specific medication and dose will be collected.
Time frame: Collected at the first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization
Percentage of Patients on Mineralocorticoid Receptor Antagonist Among Patients With Reduced Ejection Fraction
Mineralocorticoid receptor antagonist use among the sub-group of patients with left ventricular ejection fraction ≤ 40%.
Time frame: Collected at the first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization
Median Dose of Mineralocorticoid Receptor Antagonist Among Patients With Reduced Ejection Fraction
Among the sub-group of patients with left ventricular ejection fraction ≤ 40% on Mineralocorticoid Receptor Antagonist therapy, the specific medication and dose will be collected.
Time frame: Collected at the first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization
Percentage of Patients on Mineralocorticoid Receptor Antagonist Among Patients With Preserved/Mid-Range Ejection Fraction
Mineralocorticoid receptor antagonist use among the sub-group of patients with left ventricular ejection fraction \> 40%.
Time frame: Collected at the first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization
Median Dose of Mineralocorticoid Receptor Antagonist Among Patients With Preserved/Mid-Range Ejection Fraction
Among the sub-group of patients with left ventricular ejection fraction \> 40% on Mineralocorticoid Receptor Antagonist therapy, the specific medication and dose will be collected.
Time frame: Collected at the first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization
Percentage of Patients on Hydralazine/Nitrate Therapy Among African-American Patients With Reduced Ejection Fraction
Hydralazine/nitrate use among the subgroup of African-American patients with left ventricular ejection fraction ≤ 40%.
Time frame: Collected at the first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization
Median Dose of Hydralazine/Nitrate Therapy Among African-American Patients With Reduced Ejection Fraction
Among the subgroup of African-American patients with left ventricular ejection fraction ≤ 40% on hydralazine/nitrate therapy, the specific dose will be collected
Time frame: Collected at the first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization
Percentage of Patients on Sacubitril-Valsartan Therapy Among the Sub-group of Patients With Reduced Ejection Fraction
Sacubitril-valsartan use among the sub-group of patients with left ventricular ejection fraction ≤ 40%.
Time frame: Collected at the first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization
Median Dose of Sacubitril-Valsartan Therapy Among the Sub-group of Patients With Reduced Ejection Fraction
Among the sub-group of patients with left ventricular ejection fraction ≤ 40% on sacubitril-valsartan, the specific dose will be collected.
Time frame: Collected at the first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization
Percentage of Patients on Sodium/Glucose Cotransporter-2 Inhibitors Therapy Among the Sub-group of Patients With Preserved/Mid-range Ejection Fraction.
Sodium/glucose cotransporter-2 inhibitors use among the sub-group of patients with left ventricular ejection fraction ≤ 40%.
Time frame: Collected at the first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization
Percentage of Patients on Sodium/Glucose Cotransporter-2 Inhibitors Therapy Among the Sub-group of Patients With Left Ventricular Ejection Fraction > 40%.
Sodium/glucose cotransporter-2 inhibitors use among the sub-group of patients with left ventricular ejection fraction \> 40%.
Time frame: Collected at the first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization
Percentage of Patients on Ivabradine Therapy Among Patients With Reduced Ejection Fraction With a Heart Rate Above 70 Beats Per Minute on Beta-Blocker Therapy
Ivabradine use among patients with left ventricular ejection fraction ≤ 35% and a heart rate above 70 beats per minute in sinus rhythm.
Time frame: Collected at the first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization
Median Dose of Ivabradine Therapy Among Patients With Reduced Ejection Fraction With a Heart Rate Above 70 Beats Per Minute on Beta-Blocker Therapy
Among patients with left ventricular ejection fraction ≤ 35% and a heart rate above 70 beats per minute in sinus rhythm on ivabradine, the medication dose will be collected.
Time frame: Collected at the first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization
Percentage of Patients With a Implantable Cardiac Defibrillator Among Patients With Reduced Ejection Fraction
Presence of an implantable cardiac defibrillator among the sub-group of patients with left ventricular ejection fraction ≤ 35%.
Time frame: Evaluated through trial completion (first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization)
Percentage of Patients With a Cardiac Resynchronization Therapy Device Among Patients With Reduced Ejection
Presence of cardiac resynchronization therapy among the sub-group of patients with left ventricular ejection fraction ≤ 35% with electrocardiogram findings consistent with a left bundle branch block with QRS width \>150ms.
Time frame: Evaluated through trial completion (first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization)
Percentage of Patients Given Cardiac Rehabilitation Referral Among Patients With Reduced Ejection Fraction
Referral to cardiac rehabilitation among the subgroup of patients with left ventricular ejection fraction ≤ 35%.
Time frame: Evaluated through trial completion (first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization)
Number of Medication Adjustments Per Heart Failure Clinic Visit
The number of medication adjustments made at each heart failure clinic visit. These will include dose changes, new medications, and discontinuation of prior medicines.
Time frame: Within one year post-randomization
Average Daily Loop Diuretic Dose
The specific loop diuretic and dose will be collected. Diuretic doses will be converted into a standard total daily dose of loop diuretic.
Time frame: Each clinic visit over one year follow-up and first heart failure clinic visit at least one year after randomization
Count of Hospitalizations Per Patient
Heart failure hospitalizations and non-heart failure hospitalizations in the Stanford healthcare system during the follow-up period.
Time frame: Evaluated through trial completion (first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization)
Count of Emergency Department Visits Per Patient
Stanford emergency department visits during the follow-up period.
Time frame: Evaluated through trial completion (first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization)
Count of Heart Failure Clinic Visits Per Patient
Stanford heart failure clinic visits during the followup period.
Time frame: Evaluated through trial completion (first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization)
Count of Telephone Encounters Per Patient
Stanford heart failure telephone encounters during the follow-up period.
Time frame: Evaluated through trial completion (first heart failure clinic visit at least one year post-randomization or via telephone interview 15 months post-randomization)
Percentage of Patients Who Undergo Formal Advanced Heart Failure Therapy Evaluation
Formal work-up for heart transplant or LVAD (left ventricular assist device) eligibility
Time frame: Within one year post-randomization
Quality of Patient Clinic Experience
The results from a 10-question survey with ordinal responses regarding patient experience in clinic to a sub-study of all participants enrolled after the first month.
Time frame: First clinic visit post-randomization within approximately 14 days
Correlation Between Clinician and Patient Perception of Health Status
Patient and clinician perception of health status will be collected. Patient perception is collected via the KCCQ-12 while clinicians will be surveyed regarding health status. We will determine the correlation between patient and clinician perception using an ordinal scale. We will compare correlation across arms.
Time frame: First clinic visit post-randomization within approximately 14 days
Cardiovascular Diagnostic Test Frequency
Number of diagnostic tests performed between randomization and one year post-randomization. Diagnostic tests include cardiovascular imaging (echocardiography, MRI, cardiac CT, nuclear scan), invasive testing (coronary angiography, right heart catheterization), or ambulatory rhythm monitoring.
Time frame: Within one year post-randomization
Kansas City Cardiomyopathy Questionnaire-12 Score Among Patients With Heart Failure or Cardiomyopathy
The first KCCQ-12 score collected one year after randomization will be compared between the KCCQ-12 and usual care arms among patients with heart failure or cardiomyopathy The first KCCQ-12 score collected one year after randomization will be compared between the KCCQ-12 and usual care arms. KCCQ-12 scores will be collected in the usual care arm starting one year after randomization. Scores will be adjusted for baseline KCCQ-12 in both arms. This will be the primary effectiveness outcome. KCCQ-12 has 4 domains (Physical Limitation Score, Symptom Frequency Score, Quality of Life Score, Social Limitation Score) and one Summary Score. Scores are scaled 0-100, where 0 denotes the lowest reportable health status and 100 the highest.
Time frame: Collected at the first heart failure clinic visit at least one year post-randomization or via telephone interview/web questionnaire 15 months post-randomization
Kansas City Cardiomyopathy Questionnaire-12 Score Among Patients With Sub-optimal Health Status at Baseline
The first KCCQ-12 score collected one year after randomization will be compared between the KCCQ-12 and usual care arms among patients with baseline KCCQ \<100 at baseline
Time frame: Collected at the first heart failure clinic visit at least one year post-randomization or via telephone interview/web questionnaire 15 months post-randomization
Number of Total Heart Failure Medication Adjustments
The total number of heart failure medication adjustments. Heart failure medications include beta-blockers, renin-angiotensin-aldosterone system inhibitors, mineralocorticoid receptor antagonists, sodium/glucose cotransporter-2 inhibitors, hydralazine/nitrate therapy, ivabradine, or loop diuretics.
Time frame: Number of medication adjustments from randomization to one year post randomization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.